Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

792
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
792

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Interesting Case of Dengue Encephalitis With Parkinsonism Sequela.

Cureus·2023
Same author

History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.

Cancer drug resistance (Alhambra, Calif.)·2022
Same author

Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.

Gynecologic oncology·2021
Same author

The prevalence of asymptomatic COVID-19 infection in cancer patients. A cross-sectional study at a tertiary cancer center in New York City.

Cancer treatment and research communications·2021
Same author

Clinical Determinants Differentiating the Severity of SARS-CoV-2 Infection in Cancer Patients: Hospital Care or Home Recovery.

Frontiers in medicine·2021
Same author

Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The "Finer Points".

The oncologist·2020

Related Experiment Video

Updated: Sep 22, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.

Pooja Murthy1, Franco Muggia2

  • 1Department of Medicine, Maimonides Cancer Center, Brooklyn, NY 11220, USA.

Cancer Drug Resistance (Alhambra, Calif.)
|May 18, 2022
PubMed
Summary

Poly-adenosyl-ribose polymerase (PARP) inhibitors are advancing ovarian and breast cancer treatments, especially for BRCA-mutated cancers. Research is exploring their distinct indications, toxicities, and resistance mechanisms for future development.

Keywords:
BRCAbreast cancerhomologous recombination deficiencyovarian cancerpoly-adenosyl-ribose polymerase inhibitionpoly-adenosyl-ribose polymerase inhibitor resistancepoly-adenosyl-ribose polymerase inhibitors

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.3K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.4K

Related Experiment Videos

Last Updated: Sep 22, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.3K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.4K

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Poly-adenosyl-ribose polymerase (PARP) inhibitors represent a significant advancement in treating ovarian and breast cancers.
  • Their efficacy is particularly pronounced in patients with pathogenic BRCA mutations.

Purpose of the Study:

  • To review the clinical trials and approved indications for PARP inhibitors in ovarian and breast cancers.
  • To examine the pharmacological differences, emerging resistance mechanisms, and future clinical questions for PARP inhibitors.

Main Methods:

  • Review of clinical trial data and published literature on PARP inhibitors.
  • Analysis of pharmacological properties and toxicity profiles.
  • Examination of resistance mechanisms and future research directions.

Main Results:

  • Distinct clinical trial designs have led to specific indications for different PARP inhibitors.
  • Emerging toxicity patterns suggest variations in normal tissue tolerance among PARP inhibitors.
  • PARP inhibitor resistance is a growing concern in advanced ovarian and breast cancer treatment.

Conclusions:

  • PARP inhibitors have transformed treatment for BRCA-mutated ovarian and breast cancers.
  • Understanding differences in indications, toxicities, and resistance is crucial for optimizing their use.
  • Further research is needed to address key clinical questions and advance PARP inhibitor therapy.